15 Stocks Moving in Monday's Pre-Market Session



  • IceCure Medical Ltd ICCM rose 36.5% to $3.89 in pre-market trading. IceCure Medical, last week, received notice of intention to grant a European patent covering its cryogenic pump.
  • American Virtual Cloud Technologies, Inc. AVCT rose 25.8% to $2.39 in pre-market trading after dipping 24% on Thursday.
  • RISE Education Cayman Ltd REDU rose 15.3% to $0.6106 in pre-market trading following a 5% surge on Thursday.
  • Genocea Biosciences, Inc. GNCA shares rose 12.5% to $1.40 in pre-market trading after gaining around 20% on Thursday.
  • Aridis Pharmaceuticals, Inc. ARDS rose 9.8% to $2.90 in pre-market trading. Aridis Pharmaceuticals, last week, announced its fully human monoclonal antibody cocktail AR-701 is broadly reactive against the Omicron and other COVID-19 variants, SARS, MERS and the common cold coronaviruses.
  • Orbsat Corp. OSAT rose 8.4% to $4.01 in pre-market trading after dropping over 5% on Thursday. The company, last month, reported Q3 sales of $2.25 million.
  • Nxt-ID, Inc. NXTD rose 7% to $4.29 in pre-market trading after surging around 20% on Thursday.
  • Inspira Technologies Oxy B.H.N. Ltd. IINN rose 6% to $3.88 in pre-market trading after tumbling 12% on Thursday.
  • XpresSpa Group, Inc. XSPA rose 5.5% to $2.11 in pre-market trading.
  • Gevo, Inc. GEVO shares rose 5.4% to $5.10 in pre-market trading.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Check out these big penny stock gainers and losers


  • BiondVax Pharmaceuticals Ltd. BVXV fell 15.1% to $2.36 in pre-market trading after the company reported a proposed underwritten public offering of American Depositary Shares.
  • Snow Lake Resources Ltd. LITM shares fell 5.9% to $5.46 in pre-market trading after dropping over 3% on Thursday.
  • Genfit SA GNFT fell 5.9% to $5.08 in pre-market trading. Genfit and Ipsen recently announced an exclusive licensing agreement for elafibranor.
  • Sonnet BioTherapeutics Holdings, Inc. SONN shares fell 5.2% to $0.43 in pre-market trading. Chardan Capital, last week, maintained Sonnet BioTherapeutics with a Buy and lowered the price target from $8 to $2.5.
  • Ensysce Biosciences, Inc. ENSC shares fell 4.3% to $4.90 in pre-market trading. Ensysce Biosciences recently said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapPre-Market OutlookMarketsMoversTrading IdeasCommunications EquipmentInformation TechnologyPre-Market MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!